MarketPeel
Insider Trading Intelligence
GI

Gilead Sciences, Inc.

ASMB
10% OWNER · ASSEMBLY BIOSCIENCES, INC. · CIK 0000882095
FILING MIX · LIFETIME88%/12%
BUYS
23
SELLS
3
TOTAL VALUE
$650.91M
COMPANIES
4
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
76,786,115
AVG SELL PX
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
20 backtested trades · 8 horizons · 17 pending
Forward-return performance of every backtestable P/S trade by Gilead Sciences, Inc., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d20+65.00%+3.79%+1.15%+2.64%-0.85%
14d20+45.00%+0.38%+0.39%-0.01%-3.25%
30d20+45.00%+0.29%+1.94%-1.65%-2.50%
60d20+25.00%-3.44%+3.40%-6.84%-8.42%
90d20+55.00%-2.06%+4.11%-6.17%-2.20%
180d20(1 pending)+57.89%-8.73%+10.02%-18.74%-10.64%
1y20(4 pending)+25.00%-7.41%+19.44%-26.86%-40.79%
2y20(12 pending)+37.50%-17.73%+33.97%-51.70%-68.89%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ASMB · 4,977,089 shares · as of May 26, 2026
01,244,2722,488,5453,732,8174,977,08920252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 23 buys / 3 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ASMB
ASSEMBLY BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
471,698$26.50$12.50M4,977,089May 26, 2026May 27, 2026View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
3,739,000$0.53$2.00M40,384,266Feb 13, 2026Feb 17, 2026View →
XLO
XILIO THERAPEUTICS, INC.
SALE
13,335,0000Nov 26, 2025Dec 1, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
13,335,000$0.75$10.00M36,645,266Nov 26, 2025Dec 1, 2025View →
ASMB
ASSEMBLY BIOSCIENCES, INC.
PURCHASE
1,147,9601,147,960Aug 8, 2025Oct 3, 2025View →
ASMB
ASSEMBLY BIOSCIENCES, INC.
PURCHASE
1,147,9601,147,960Aug 8, 2025Oct 3, 2025View →
ASMB
ASSEMBLY BIOSCIENCES, INC.
PURCHASE
2,295,9204,505,391Aug 8, 2025Oct 3, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
13,335,00023,310,266Jun 5, 2025Jun 6, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
13,335,00013,335,000Jun 5, 2025Jun 6, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
13,335,00013,335,000Jun 5, 2025Jun 6, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
13,335,00013,335,000Jun 5, 2025Jun 6, 2025View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASE
1,363,636$11.00$15.00M31,424,760Feb 18, 2025Feb 20, 2025View →
ASMB
ASSEMBLY BIOSCIENCES, INC.
PURCHASE
940,499$21.37$20.10M2,209,471Dec 19, 2024Dec 23, 2024View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
1,759,978$1.04$1.83M9,105,451Dec 18, 2024Dec 19, 2024View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
6,092,816$1.04$6.34M9,975,266Dec 18, 2024Dec 19, 2024View →
ASMB
ASSEMBLY BIOSCIENCES, INC.
PURCHASE
179,500179,500Jun 17, 2024Jun 20, 2024View →
ASMB
ASSEMBLY BIOSCIENCES, INC.
PURCHASE
179,5001,268,972Jun 17, 2024Jun 20, 2024View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
3,882,450$0.76$2.95M3,882,450Apr 2, 2024Apr 3, 2024View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
485,250$0.76$368.8K7,345,473Apr 2, 2024Apr 3, 2024View →
KYTX
KYVERNA THERAPEUTICS, INC.
PURCHASE
3,216,1193,216,119Feb 12, 2024Feb 13, 2024View →
KYTX
KYVERNA THERAPEUTICS, INC.
PURCHASE
910,000$22.00$20.02M4,126,119Feb 12, 2024Feb 13, 2024View →
KYTX
KYVERNA THERAPEUTICS, INC.
SALE
6,890,7440Feb 12, 2024Feb 13, 2024View →
KYTX
KYVERNA THERAPEUTICS, INC.
SALE
7,746,1390Feb 12, 2024Feb 13, 2024View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASE
15,238,095$21.00$320.00M30,061,124Jan 29, 2024Jan 31, 2024View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASE
1,010,000$19.26$19.45M14,823,029Jun 28, 2023Jun 30, 2023View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASE
5,650,000$39.00$220.35M13,913,029Jan 31, 2021Feb 2, 2021View →
Other insiders · ASMB
Loading peer insiders…
About this filer
CIK 0000882095
ROLE
10% Owner
PRIMARY
ASMB
COMPANIES
4
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0000882095DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback